FGFR1 and mantle cell lymphoma: Interestingly, the expression of MYC is significantly lower in either shRNA FGFR1 or erdafitinib-treated MCL cells compared to control (Fig. 6B-C, Fig. S6D), but the expression of MYC was unaltered (Fig. S6B-C).